曲伐沙星对肺炎衣原体的体外活性。
In vitro activity of trovafloxacin against Chlamydia pneumoniae.
作者信息
Roblin P M, Kutlin A, Hammerschlag M R
机构信息
Department of Pediatrics, State University of New York Health Science Center at Brooklyn, 11203, USA.
出版信息
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
Abstract
The in vitro susceptibilities of 12 strains of Chlamydia pneumoniae to a new quinolone, trovafloxacin, and ofloxacin, doxycycline, erythromycin, and azithromycin were determined. The activity of trovafloxacin was similar to that of ofloxacin, with a MIC at which 90% of the isolates are inhibited and a minimal concentration at which 90% of the isolates are killed of 1.0 microg/ml, but trovafloxacin was less active than doxycycline, erythromycin, and azithromycin.
摘要
测定了12株肺炎衣原体对新型喹诺酮类药物曲伐沙星、氧氟沙星、多西环素、红霉素和阿奇霉素的体外敏感性。曲伐沙星的活性与氧氟沙星相似，90%分离株被抑制的最低抑菌浓度（MIC）和90%分离株被杀灭的最低浓度均为1.0微克/毫升，但曲伐沙星的活性低于多西环素、红霉素和阿奇霉素。
相似文献
1
In vitro activity of trovafloxacin against Chlamydia pneumoniae.曲伐沙星对肺炎衣原体的体外活性。
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
2
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.新型8-甲氧基喹诺酮BAY 12-8039对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
3
In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.吉米沙星（SB 265805，LB20304）对近期肺炎衣原体临床分离株的体外活性。
Antimicrob Agents Chemother. 1999 Nov;43(11):2806-7. doi: 10.1128/AAC.43.11.2806.
4
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.阿奇霉素、克拉霉素、左旋氧氟沙星及其他抗生素对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573.
5
In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.与培氟沙星、环丙沙星、氧氟沙星、多西环素和克拉霉素相比，伯氏考克斯体对曲伐沙星的体外敏感性。
Antimicrob Agents Chemother. 1998 Oct;42(10):2747-8. doi: 10.1128/AAC.42.10.2747.
6
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.新型喹诺酮类药物OPC - 17116、氧氟沙星及司帕沙星对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1994 Jun;38(6):1402-3. doi: 10.1128/AAC.38.6.1402.
7
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).肺炎支原体、人型支原体和解脲脲原体对新型喹诺酮类药物曲伐沙星（CP-99,219）的敏感性
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
8
In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.与五种抗菌药物相比，曲伐沙星对包括人型支原体和解脲脲原体在内的支原体的体外活性，这些支原体为已进行基因特征分析的耐氟喹诺酮分离株。
Antimicrob Agents Chemother. 2000 Sep;44(9):2557-60. doi: 10.1128/AAC.44.9.2557-2560.2000.
9
In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.左氧氟沙星对来自北美和欧洲的嗜肺军团菌、肺炎支原体和肺炎衣原体当代临床分离株的体外活性。
Clin Microbiol Infect. 2002 Apr;8(4):214-21. doi: 10.1046/j.1469-0691.2002.00392.x.
10
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.阿奇霉素、克拉霉素、红霉素和四环素对13株肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1996 Jan;40(1):212-4. doi: 10.1128/AAC.40.1.212.
引用本文的文献
1
The new fluoroquinolones: A critical review.新型氟喹诺酮类药物：批判性综述。
Can J Infect Dis. 1999 May;10(3):207-38. doi: 10.1155/1999/378394.
2
Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.阿奇霉素缓释剂：美国治疗急性细菌性鼻窦炎和社区获得性肺炎的应用综述
Drugs. 2007;67(5):773-92. doi: 10.2165/00003495-200767050-00010.
3
A critical review of the fluoroquinolones: focus on respiratory infections.氟喹诺酮类药物的批判性综述：聚焦于呼吸道感染
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
4
[Role of new fluoroquinolones in respiratory infections in primary care].[新型氟喹诺酮类药物在基层医疗中呼吸道感染治疗中的作用]
Aten Primaria. 2000 Apr 30;25(7):512-7. doi: 10.1016/s0212-6567(00)78557-x.
5
Activity of quinolones against Chlamydia pneumoniae.喹诺酮类药物对肺炎衣原体的活性。
Drugs. 1999;58 Suppl 2:78-81. doi: 10.2165/00003495-199958002-00015.
6
In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.吉米沙星（SB 265805，LB20304）对近期肺炎衣原体临床分离株的体外活性。
Antimicrob Agents Chemother. 1999 Nov;43(11):2806-7. doi: 10.1128/AAC.43.11.2806.
7
Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.曲伐沙星与大剂量阿莫西林（每日三次，每次1g）治疗社区获得性细菌性肺炎的比较
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):447-53. doi: 10.1007/BF01691581.
8
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.新型喹诺酮类药物曲伐沙星对呼吸道病原体的细菌学活性。
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):405-12. doi: 10.1007/BF01691573.
9
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.新型酮内酯类抗生素HMR 3647对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Jun;42(6):1515-6. doi: 10.1128/AAC.42.6.1515.
10
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.新型8-甲氧基喹诺酮BAY 12-8039对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
本文引用的文献
1
Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.曲伐沙星，一种对肺炎链球菌具有强效活性的新型氟喹诺酮类药物。
Antimicrob Agents Chemother. 1997 Feb;41(2):478-80. doi: 10.1128/AAC.41.2.478.
2
In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.曲伐沙星（CP-99,219）、司帕沙星、环丙沙星和氟罗沙星对呼吸道病原体的体外活性。
Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):696-8. doi: 10.1007/BF01691164.
3
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).肺炎支原体、人型支原体和解脲脲原体对新型喹诺酮类药物曲伐沙星（CP-99,219）的敏感性
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
4
Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.曲伐沙星在健康志愿者中的多剂量药代动力学及安全性
J Antimicrob Chemother. 1996 May;37(5):955-63. doi: 10.1093/jac/37.5.955.
5
Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.氧氟沙星与标准疗法治疗需住院的社区获得性肺炎的对比研究。肺炎研究组。
Antimicrob Agents Chemother. 1996 May;40(5):1175-9. doi: 10.1128/AAC.40.5.1175.
6
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.新型喹诺酮类药物OPC - 17116、氧氟沙星及司帕沙星对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1994 Jun;38(6):1402-3. doi: 10.1128/AAC.38.6.1402.
7
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.小儿社区获得性肺炎中的肺炎支原体和肺炎衣原体：克拉霉素与琥乙红霉素的疗效及安全性比较
Pediatr Infect Dis J. 1995 Jun;14(6):471-7. doi: 10.1097/00006454-199506000-00002.
8
Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.氧氟沙星治疗肺炎衣原体（TWAR株）下呼吸道感染
Am J Med. 1990 Dec;89(6):722-4. doi: 10.1016/0002-9343(90)90212-v.
9
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.一种新的呼吸道病原体：肺炎衣原体TWAR株。
J Infect Dis. 1990 Apr;161(4):618-25. doi: 10.1093/infdis/161.4.618.
10
Infection with Chlamydia pneumoniae in Brooklyn.布鲁克林地区肺炎衣原体感染情况。
J Infect Dis. 1991 Apr;163(4):757-61. doi: 10.1093/infdis/163.4.757.
Zotero 插件